1.4(top 11%)
Impact Factor
1.5(top 11%)
extended IF
40(top 10%)
H-Index
authors
838
papers
9.2K
citations
citing journals
citing authors

Most Cited Articles of P and T

TitleYearCitations
The antibiotic resistance crisis: part 1: causes and threats20151.4K
Medical Applications for 3D Printing: Current and Projected Uses2014339
Progress in Nanomedicine: Approved and Investigational Nanodrugs2017301
Mobile devices and apps for health care professionals: uses and benefits2014285
Social media and health care professionals: benefits, risks, and best practices2014250
Multiple sclerosis review2012226
Interpreting estimates of treatment effects: implications for managed care2008178
Osteoporosis: A Review of Treatment Options2018124
The antibiotic resistance crisis: part 2: management strategies and new agents2015123
Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis2015119
Schizophrenia: overview and treatment options2014118
How patient cost-sharing trends affect adherence and outcomes: a literature review2012106
Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment2010100
Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting201792
Personalized medicine: part 1: evolution and development into theranostics201091
Cancer Immunotherapy, Part 3: Challenges and Future Trends201790
Drugs for Alzheimer's disease: are they effective?201088
The burden of psoriatic arthritis: a literature review from a global health systems perspective201083
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma201077
The drug shortage crisis in the United States: causes, impact, and management strategies201176
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use201272
Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths200970
Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer201168
Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?201162
The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma201362